T Cell Based Immunotherapy: A Deeper Dive III

February 28th - March 3rd 2019

This conference will bring together some of the most talented scientists involved with understanding T cell function and will promote discussions for possible therapeutic intervention in the setting of tumor immunology. Its unique “think tank” format allows for lots of discussion to further dissect the intricacies of T cell function in tumor-bearing hosts. We also want to emphasize that while the meeting will be intense and thought provoking; the venue lends itself to having fun and relaxing. Hence, getting away from the rigors of the lab to the lush shores of Wailea will provide a creative atmosphere that will spawn new ideas in T cell biology.

Located at the Fairmont Kea Lani in Maui Hawaii

 Thursday, February 28, 2019

Welcome Reception
*Sponsored By Thermo Fisher Scientific*

 Friday, March 1st

Robert Schreiber, Washington University School of Medicine in St. Louis
”High Dimensional Profiles of Successful vs Unsuccessful Cancer Immunotherapy”
James Allison, MD Anderson
Immune Checkpoint Blockade in Cancer Therapy: New insights, opportunities, and prospects for cures”
Dario Vignali, University of Pittsburgh
”Inhibitory Mechanisms in the Tumor Microenvironment”
Anthony Vella, UCONN Health
"Examining power of dual costimulation through CD134 and CD137 in T cells"
Bernard Fox, Earle A. Chiles Research Institute, Providence Cancer Institute
"Evolving Concepts of Anticancer Immunity that May Help to #FinishCancer"
Carl Ware, Sanford Burnham Prebys Medical Discovery Institute
"Impact of the HVEM Network in Controlling Immune Function"
Andrew Weinberg, Earle A. Chiles Research Institute, Providence Cancer Institute
“Targeting tumor-reactive T cells through anti-OX40 and TGFb receptor blockade”

Saturday, March 2nd

Stephen Hedrick, UC San Diego
”T Cell Programming for Immunotherapy”
Randy Noelle, Dartmouth
”VISTA: T cell tolerance, TME remodelling and it’s impact on tumor immunity.”
Phil Greenberg, University of Washington
”Engineering T cells to eradicate malignancies”
Erika Pearce, Max Planck Institute of Immunobiology and Epigenetics
”T-Cell Metabolism”
Douglas Green, St. Judes Childrens Research Hospital
”LC3-associated phagocytosis and anti-cancer immunity”
Greg Delgoffe, University of Pittsburgh
”Fueling effective cancer immunotherapy through metabolic reprogramming”
John Wherry, University of Pennsylvania
”Molecular Mechanisms of T Cell Exhaustion”
Samir Khlief, Georgetown University
”Overcoming PD1 Resistance”

Sunday, March 3rd

Jedd Wolchok, Memorial Sloan Kettering Cancer Center
”Exploring Mechanisms for Checkpoint Blockade”
Carl June, University of Pennsylvania
”Designing better CARs”
Padmanee Sharma, MD Anderson
”From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy.”
Robert Ferris, University of Pittsburgh
“Analysis of intratumoral mechanisms of escape and immunotherapeutic resistance using neoadjuvant clinical trials”
Brendan Curti, Earle A. Chiles Research Institute, Providence Cancer Institute
”Neoadjuvant OX40 Co-stimulation & TIL”
James Heath, Institute for Systems Biology
”Molecular view of Cancer Immunotherapy”
Eric Tran, Earle A. Chiles Research Institute, Providence Cancer Institute
”Tumor genome guided adoptive T-cell transfer therapy”
Kelly Paulson, Fred Hutchinson Cancer Research Center
”Mechanistic insights into late cancer escape from T cell immunotherapy as revealed by scRNAseq”

Thank You to Our Sponsors

Updated Agenda.png